Drug Type Small molecule drug |
Synonyms 4-(6-Methoxy-2-naphthalenyl)-2-butanone, 4-(6-Methoxy-2-naphthyl)-2-butanone, Nabumetone (JP17/USP/INN) + [10] |
Target |
Action inhibitors |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date (01 Jan 1984), |
RegulationOrphan Drug (United States) |
Molecular FormulaC15H16O2 |
InChIKeyBLXXJMDCKKHMKV-UHFFFAOYSA-N |
CAS Registry42924-53-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00425 | Nabumetone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoarthritis | United States | 24 Dec 1991 | |
Low Back Pain | Japan | 30 Mar 1990 | |
Musculoskeletal Diseases | Japan | 30 Mar 1990 | |
Rheumatoid Arthritis | Japan | 30 Mar 1990 | |
Pain | - | 01 Jan 1984 | |
Soft Tissue Injuries | - | 01 Jan 1984 |
Not Applicable | - | - | sdrtytoieb(vgepznkroa) = szxobitxsj khtxamqjry (jbigqldhkk, 1.0) View more | - | 01 Oct 2020 | ||
sdrtytoieb(vgepznkroa) = jiwdpmfxzl khtxamqjry (jbigqldhkk, 1.2) View more | |||||||
Not Applicable | 2,020 | dulxxhbmoa(bmzkagsxhi) = The incidence of adverse events including hypertension and lower extremity edema was similar among active treatments nbnrkledov (oscadcyvyk ) | Positive | 18 Jun 2003 | |||